secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0000950170-23-051118
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure
--------------------------------------------------------------------------------

- Nasdaq notified Galecto that common stock bid price closed below $1.00 for 30 consecutive business days.
- Company has until March 25, 2024 to regain compliance with Minimum Bid Price Requirement.
- If not cured, Galecto may qualify for a second 180-day period by transferring to Nasdaq Capital Market.
- Galecto may consider a reverse stock split to regain compliance, but no assurance of success.
- Common stock symbol GLTO continues trading on Nasdaq Global Select Market pending compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023051118/0000950170-23-051118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023051118/glto-20230927.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-051118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer